Success Item Removed From Cart

Basket Summary
Close

Your Cart is Empty

Subtotal
$0
Sales Tax
$0
Total
$0
Back to browsing

Overview

How likely is it that the drugs in Burns will get approved? Will the drugs transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LoA) and phase transition success rate (PTSR) of drugs using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.

Burns Overview

Burns result from tissue damage caused by heat, chemicals, electricity, or radiation, with severity ranging from mild to life-threatening. Classification into first, second, or third-degree burns depends on the depth and extent of tissue involvement. Immediate treatment aims to stop the burning process, cool the affected area, and prevent infection. Severe burns may require hospitalization, including fluid resuscitation, wound debridement, and skin grafting. Complications such as infection, scarring, and long-term physical or psychological effects are common. Prevention through safety measures like smoke detectors, fire extinguishers, and proper handling of hot objects is crucial in reducing the incidence of burns.

Report Coverage

The data is segmented by drug name per indication and shows the current likelihood of approval for industry benchmarks and drug comparisons.
The Likelihood of Approval data is updated regularly based on events that take place which impact the clinical development process and regulatory considerations. GlobalData’s proprietary machine learning models consider these events in real time, to produce quantitative changes to the LOA and PTSR along with qualitative reasoning why the likelihood of approval has changed.

Reasons to buy

  • Predict the specific likelihood of approval and phase transition success rates of a drug using a combination of machine learning and proprietary models
  • Get information on LOA and PTSR for competitors’ drugs to plan your clinical development, commercialization and marketing strategies
  • Track event-driven changes in LOA and PTSR benchmarked against indication LOA/PTSR
  • Use PTSR and LOA information and event-driven changes for your investment decisions.

What our clients have to say

More Reports

View More Reports